Patent intelligence · US
US 2020199221
ANTIBODIES USEFUL IN CANCER DIAGNOSIS
ANTIBODIES USEFUL IN CANCER DIAGNOSIS
Patent details — US 2020199221
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 25, 2020
- Expiration
- Jun 20, 2040
- Applicant
- ASTELLAS PHARMA INC [JP]
- CPC classes
- A61K 47/ 68 A I, A61K/476849
Quick answer
US 2020199221 (ANTIBODIES USEFUL IN CANCER DIAGNOSIS) is held by ASTELLAS PHARMA INC [JP]. Status: granted. Granted Jun 25, 2020. Expires Jun 20, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASTELLAS PHARMA INC [JP]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 47/ 68 A I, A61K/476849
More from ASTELLAS PHARMA INC [JP]
Related pharmaceutical patents in our USPTO index.
-
AU 2022206771
Drug conjugates comprising antibodies against Claudin 18.2
granted -
EP 3791896
KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS
granted -
LT 3254695
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted -
EP 3708579
CLAUDIN-6-SPEZIFISCHE IMMUNREZPTOREN UND T-ZELL-EPITOPE
granted -
HR P20200591
ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)
granted -
WO 2020095183
COMBINAISON POUR LE TRAITEMENT DU CANCER
granted -
US 2019076525
THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted
Frequently asked questions
What is US patent 2020199221?
US 2020199221 (ANTIBODIES USEFUL IN CANCER DIAGNOSIS) is held by ASTELLAS PHARMA INC [JP]. Status: granted. Granted Jun 25, 2020. Expires Jun 20, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2020199221?
ASTELLAS PHARMA INC [JP] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2020199221 expire?
Our index shows an expiration date of Jun 20, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.